Key Background and Data from ASCENT-03

The ASCENT-03 trial, presented at ESMO and published in NEJM, evaluated sacituzumab govitecan (SG) versus physician’s-choice chemotherapy—including paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin—in patients with metastatic TNBC who were either PD-L1–negative or not candidates for immunotherapy. This addressed a major unmet need, as nearly 60% of real-world mTNBC patients would not have qualified for earlier. The results from this study reinforce SG as a meaningful alternative for patients lacking IO eligibility.